COVID-19疫情期间的ECMO:从抢救治疗转向更合理的适应证
该文讨论COVID-19相关重度ARDS中ECMO的应用演变,指出疫情导致机械通气患者激增,ECMO使用增多;随着治疗经验积累、地塞米松及托珠单抗等药物应用和疫苗接种推进,COVID-19结局动态改善,ECMO正从挽救性治疗向具有明确适应证的标准化治疗选项转变。
要点
- COVID-19疫情使机械通气患者数量空前增加,其中不少为重度ARDS。
- ECMO在疫情期间被频繁应用,使用情况受各国医疗系统资源影响。
- 地塞米松、托珠单抗及疫苗接种等进展改变了COVID-19重症呼吸衰竭的结局。
核心结论
- ECMO在COVID-19相关ARDS中的定位正从挽救性治疗转向具有明确适应证的标准化治疗选项。
主要发现
- COVID-19导致机械通气患者数量空前增加,许多患者表现为重度ARDS。
- 疫情期间ECMO被频繁应用,具体使用受国家医疗系统资源影响。
- 2020年夏季引入地塞米松,2021年在疾病早期重症阶段加用托珠单抗。
- 疫苗接种规划启动对重度呼吸衰竭结局产生重要影响。
临床怎么用
- 在COVID-19相关重度ARDS中,应将ECMO视为具有明确适应证的标准化治疗选项而非仅挽救治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Shedding new light on ECMO treatment in ARDS: moving from rescue therapy to a standardised treatment option with defined indications https://bit.ly/3zXAhyF Coronavirus disease 2019 (COVID-19) led to an unprecedented number of patients on mechanical ventilation, many of them presenting with severe acute respiratory distress syndrome (ARDS) [1–4]. Depending on the resources of national healthcare systems, extracorporeal membrane oxygenation (ECMO) was frequently applied during the pandemic [3, 5–7]. While intensive care unit experience improved with this new disease, various forms of drug therapies were introduced in living guidelines, resulting in a dynamic development in outcome of COVID-19 [8, 9]. Particularly noteworthy was the introduction of dexamethasone in the summer of 2020, and in 2021 the additional administration of tocilizumab in the early severe phase of the disease [10]. A third important factor that had a significant impact on the outcome of severe respiratory failure was the start of vaccination programmes, primarily for risk groups, depending on national strategies, followed by the general public.
引用
- Karagiannidis C, Bein T, Welte T, et al. ECMO during the COVID-19 pandemic: moving from rescue therapy to more reasonable indications. Eur Respir J. 2022. PMID: 35115345. doi:10.1183/13993003.03262-2021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。